What this pack is
Toprol-XL is the brand name in this record; metoprolol succinate is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
Toprol-XLGeneric namemetoprolol succinate
Mainland China pack-name cue倍他乐克®缓释片Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The FDA public label describes metoprolol as a beta1-selective (cardioselective) adrenergic-receptor blocker; this selectivity is not absolute. It also explains that TOPROL-XL uses multiple controlled-release pellets designed to release metoprolol continuously across the dosing interval. This describes mechanism and formulation design, not an individual's dose change, stopping or combination plan.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 倍他乐克®缓释片
- International brand name
- Toprol-XL
- Source-scoped market brand names
- 倍他乐克®缓释片 · Mainland China (AstraZeneca China public product list)Source-scoped evidence ↗AstraZeneca China's product list maps Betaloc ZOK® to metoprolol succinate extended-release tablets and lists 47.5 mg and 95 mg. This is only a China pack-name search route; the dossier remains the U.S. TOPROL-XL 25/50/100/200 mg product, and cross-market strengths and packages must not be merged or converted.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- metoprolol succinate
- Dosage-form class
- Extended-release oral tablets: 25 mg, 50 mg, 100 mg and 200 mg (as listed in the current 2026 DailyMed label)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:倍他乐克®缓释片. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
The label states that these four TOPROL-XL extended-release tablets are scored and may be divided; do not crush or chew either a whole or half tablet. This label-specific fact does not transfer to another metoprolol product, market or presentation.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v7, updated 3 Mar 2026 and published 6 Mar 2026
25 mg per tablet; 100-tablet bottle (extended-release tablet)
- Product code
- NDC 70842-110-02
- Form and route
- TOPROL-XL metoprolol succinate extended-release oral tablet · oral
- Container
- 100-tablet bottle
- metoprolol succinate
- 25 mglabelled strength per tablet; not an individual tablet-count, splitting or conversion rule
- Package
- 100 tablets per bottle
- Labelled appearance
- white · oval biconvex film-coated tablet · imprint A/βScored in this labelled presentation
United States label · DailyMed SPL v7, updated 3 Mar 2026 and published 6 Mar 2026
50 mg per tablet; 100-tablet bottle (extended-release tablet)
- Product code
- NDC 70842-111-02
- Form and route
- TOPROL-XL metoprolol succinate extended-release oral tablet · oral
- Container
- 100-tablet bottle
- metoprolol succinate
- 50 mglabelled strength per tablet; not an individual tablet-count, splitting or conversion rule
- Package
- 100 tablets per bottle
- Labelled appearance
- white · round biconvex film-coated tablet · imprint A/moScored in this labelled presentation
United States label · DailyMed SPL v7, updated 3 Mar 2026 and published 6 Mar 2026
100 mg per tablet; 100-tablet bottle (extended-release tablet)
- Product code
- NDC 70842-112-02
- Form and route
- TOPROL-XL metoprolol succinate extended-release oral tablet · oral
- Container
- 100-tablet bottle
- metoprolol succinate
- 100 mglabelled strength per tablet; not an individual tablet-count, splitting or conversion rule
- Package
- 100 tablets per bottle
- Labelled appearance
- white · round biconvex film-coated tablet · imprint A/msScored in this labelled presentation
United States label · DailyMed SPL v7, updated 3 Mar 2026 and published 6 Mar 2026
200 mg per tablet; 100-tablet bottle (extended-release tablet)
- Product code
- NDC 70842-113-02
- Form and route
- TOPROL-XL metoprolol succinate extended-release oral tablet · oral
- Container
- 100-tablet bottle
- metoprolol succinate
- 200 mglabelled strength per tablet; not an individual tablet-count, splitting or conversion rule
- Package
- 100 tablets per bottle
- Labelled appearance
- white · oval biconvex film-coated tablet · imprint A/mYScored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
TOPROL-XL label reading: a similar metoprolol name does not erase release form
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the 2026 U.S. DailyMed public label as a reading entry point. It separates TOPROL-XL, metoprolol succinate, extended-release oral tablets, 25/50/100/200 mg and exact bottles; it does not decide an individual's amount, switch or combination with another cardiovascular medicine.
- Check TOPROL-XL, metoprolol succinate, extended-release tablet, stated strength per tablet and target market together. A shared “metoprolol” name or similar number does not prove products can be self-converted, substituted or alternated by tablet count.
- “Extended release” describes a formulation's release design across the dosing interval; it is not a universal claim of being “stronger” or freely crushable. Splitting, swallowing method or changing to another form can only be confirmed from the current label for that exact product and a pharmacist.
- The label identifies situations needing extra review with clonidine, digoxin or some calcium-channel blockers, and warns against self-directed abrupt discontinuation. With heart-rate changes, dizziness, chest discomfort or a changed medicine list, bring the actual pack to a clinician or pharmacist rather than self-adjusting or stopping from a webpage.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. TOPROL-XL metoprolol succinate public label (Melinta; SPL v7, updated 3 Mar 2026) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Toprol-XL (metoprolol succinate). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Toprol-XL is the brand in this record and metoprolol succinate is the active-ingredient name. Check both with the dosage form (Extended-release oral tablets: 25 mg, 50 mg, 100 mg and 200 mg (as listed in the current 2026 DailyMed label)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When LOPRESSOR / metoprolol tartrate is on the same list: first separate extended-release and standard tablets
The U.S. public label identifies TOPROL-XL as an extended-release metoprolol succinate tablet, while LOPRESSOR is a standard metoprolol tartrate oral tablet. A shared ‘metoprolol’ name or similar mg number only signals that both actual packs and the complete medicine list need pharmacist or prescriber review; this card does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the LOPRESSOR / metoprolol tartrate record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20HOW IT WORKS · NOT A TREATMENT PLAN
How metoprolol succinate works: it mainly blocks cardiac beta1 adrenergic receptors
- “Mainly beta1” does not mean the effect is confined to the heart in every person, and it cannot decide by itself whether coexisting lung disease, a low heart rate, dizziness or another medicine is compatible. Have a clinician or pharmacist review the full situation.
- An extended-release mechanism does not automatically mean a tablet cannot be divided. The FDA label for this exact TOPROL-XL product says scored tablets may be divided but whole or half tablets must not be crushed or chewed; other metoprolol products or market labels can differ, so do not generalize this rule.
- A shared mechanism also cannot decide how to combine with clonidine, digoxin, calcium-channel blockers or when to interrupt treatment. With an abnormal heart rate, dizziness, chest discomfort or a changed medicine list, take the actual pack to the prescribing team or pharmacist for review.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. TOPROL-XL metoprolol succinate public label (Melinta; SPL v7, updated 3 Mar 2026) ↗reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Toprol-XLmetoprolol succinate
This page links to public primary-source material for Toprol-XL. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the FDA label
The FDA label archive linked here lists Initial U.S. Approval: 1992. This historical locator is not a conclusion about current approval, availability, holder or another market.
DailyMed: TOPROL-XL current public label ↗FDA label archive version
This page links the 2026-03 FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
DailyMed: TOPROL-XL current public label ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 倍他乐克®缓释片
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.